Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis

What is it about?

Non- alcoholic steato-hepatitis (NASH) associates with an increased risk to develop cardiovascular complications and mortality suggesting that treatment of NASH might benefit from combined approaches that target the liver and cardiovascular components of NASH. By genetic and pharmacologic approaches we demonstrate that GPBAR1 agonism reverses liver and vascular damage in mouse models of NASH.

Featured Image